Vipin Kumar

Company: GRI Bio

Job title: Co-Founder & Chief Scientific Officer

Seminars:

Translating GRI 0621 from Preclinical Models to Phase 2a IPF Signals 9:00 am

Highlight the impact of GRI 0621 in resolving inflammation and fibrosis in preclinical bleomycin-induced models and how this informed clinical design Review preliminary Phase 2a results in IPF patients and discuss implications for dose, patient selection, and endpoint refinement Explore how early clinical insights are feeding back into preclinical strategy to sharpen target validation and…Read more

day: Conference Day Two